https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Determinants of pregnant women's compliance with alcohol guidelines: a prospective cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12931 Wed 11 Apr 2018 17:11:41 AEST ]]> Provision of antenatal smoking cessation support: a survey with pregnant Aboriginal and Torres Strait Islander women https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27683 Wed 11 Apr 2018 11:19:38 AEST ]]> Tobacco, alcohol and cannabis use during pregnancy: clustering of risks https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17462 Wed 11 Apr 2018 09:18:36 AEST ]]> Receipt of information about diet by pregnant women: a cross-sectional study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47615 Tue 24 Jan 2023 11:56:50 AEDT ]]> Prevalence and factors associated with antenatal care service access among Indigenous women in the Chittagong Hill Tracts, Bangladesh: A cross-sectional study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41965 Tue 16 Aug 2022 14:45:52 AEST ]]> Delaying factors for maternal health service utilization in eastern Ethiopia: a qualitative exploratory study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39113 Tue 10 May 2022 14:47:41 AEST ]]> Antenatal care use in Ethiopia: a spatial and multilevel analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36724 Thu 04 Nov 2021 10:39:48 AEDT ]]> General practice registrars' experiences of antenatal care: a cross-sectional analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39988 Fri 15 Jul 2022 10:14:56 AEST ]]> Single dose v two-dose antenatal anti-D prophylaxis: a randomised controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46858 P < 0.001). Compliance was not significantly different between the single dose (86 of 138, 61%) and two‐dose groups (70 of 139, 50%; P = 0.06). Conclusions: The two‐dose RAADP schedule currently recommended in Australia provides better protection against Rh(D) sensitisation than a one‐dose regimen. Trial registration: Australian and New Zealand Clinical Trials Registry (ACTRN12613000661774).]]> Fri 02 Dec 2022 11:01:30 AEDT ]]>